NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.91 +0.89 (+1.14%) GOLD FUTURES
2,392.70 +32.80 (+1.39%) DOW
39,908.00 +349.89 (+0.88%) Bitcoin GBP
51,903.82 +3,340.31 (+6.88%)
PhotoCure ASA (PHO.OL)
| Previous close | 62.80 |
| Open | 62.80 |
| Bid | 60.30 x 140900 |
| Ask | 60.80 x 97900 |
| Day's range | 59.60 - 62.80 |
| 52-week range | 40.70 - 71.90 |
| Volume | |
| Avg. volume | 87,589 |
| Market cap | 1.632B |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | 1,505.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 23 May 2013 |
| 1y target est | N/A |
- PR Newswire
Photocure ASA: Results for the first quarter of 2024
Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 116.8 million in the first quarter of 2024 (Q1 2023: NOK 105.9 million), and EBITDA of NOK 7.9 million (NOK -1.2 million) following positive operational developments and cost control. The Company reiterates its business and financial guidance for 2024 with 40 to 70 new and upgraded Saphira™ blue light tower installations during the year, product revenue growth of 6% to 9% in constant currency, and positive EBITDA excluding b
- PR Newswire
Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for the regulatory review of Cevira® (APL-1702, Hexaminolevulinate Hydrochloride Ointment Photodynamic Therapy System) for potential marketing authorization in China. Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non
- PR Newswire
Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the AUA 2024: the American Urological Association Annual Congress 2024 was held May 3-6, 2024, in San Antonio, TX, USA. The results of the BRAVO study performed within the VA healthcare system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a blue light cystoscop
